{"id":"W2201190784","doi":"10.1056/nejmoa1505654","title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1320,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Internal medicine; Multiple myeloma; Progression-free survival; Oncology; Neutropenia; Hazard ratio; Bortezomib; Dexamethasone; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006438798,0.0003975139,0.0009354794,0.0003140072,0.0002620131,0.0002410194,0.0003056586,0.0003034359,0.001391976],"category_scores_gemma":[0.0005135647,0.00008099729,0.0003400737,0.0002851248,0.0002266437,0.0001606207,0.0002044231,0.0004877088,0.000314455],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006029469,"about_ca_system_score_gemma":0.0002840737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002089879,"about_ca_topic_score_gemma":0.0005802418,"domain_scores_codex":[0.9998007,0.0000678696,0.00002131735,0.00002906579,0.00004676988,0.00003434544],"domain_scores_gemma":[0.9998337,0.00005536696,0.00004939538,0.0000109312,0.00001186074,0.00003870408],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.07570059,0.006833416,0.04021426,0.00227533,0.001530987,0.003690834,0.0004831071,0.004354277,0.05961322,0.0006750262,0.005700724,0.7989283],"study_design_scores_gemma":[0.2174842,0.244204,0.331786,0.001151662,0.003354262,0.02618555,0.0003484936,0.01200489,0.04804987,0.003671702,0.1116394,0.0001199133],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833407,0.01392675,0.0006179089,0.0003266571,0.00006992619,0.0002009323,0.0001267848,0.0000424284,0.001347843],"genre_scores_gemma":[0.9924787,0.004724553,0.0008633718,0.0004586055,0.0001324992,0.0001749779,0.0003807949,0.000006039217,0.0007804141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001391976,"threshold_uncertainty_score":0.004656613,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09997258122392107,"score_gpt":0.365146460681726,"score_spread":0.265173879457805,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}